Free Trial

ProKidney (PROK) Stock Price, News & Analysis

-0.14 (-3.99%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
317,888 shs
Average Volume
756,355 shs
Market Capitalization
$772.88 million
P/E Ratio
Dividend Yield
Price Target

ProKidney MarketRank™ Stock Analysis

Analyst Rating
2.33 Rating Score
181.9% Upside
$9.50 Price Target
Short Interest
22.89% of Float Sold Short
Dividend Strength
News Sentiment
0.58mentions of ProKidney in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$302,723 Sold Last Quarter
Proj. Earnings Growth
From ($0.61) to ($0.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.08 out of 5 stars

Medical Sector

485th out of 917 stocks

Biological Products, Except Diagnostic Industry

72nd out of 152 stocks

PROK stock logo

About ProKidney Stock (NASDAQ:PROK)

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

PROK Stock Price History

PROK Stock News Headlines

PROK Apr 2024 5.000 put
ProKidney assumed with an Equal Weight at Morgan Stanley
PROK Mar 2024 7.500 call
ProKidney (NASDAQ: PROK)
BTIG Reaffirms Their Buy Rating on ProKidney (PROK)
PROK Jan 2024 10.000 call
See More Headlines
Receive PROK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
($4.78) per share


Free Float
Market Cap
$772.88 million
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Timothy A. Bertram D.V.M. (Age 69)
    Ph.D., Founder
    Comp: $970.4k
  • Mr. Todd C. Girolamo Esq. (Age 59)
    J.D., M.B.A., Chief Legal Officer & Secretary
    Comp: $600.17k
  • Dr. Bruce Culleton M.D.
    CEO & Director
  • Mr. James Coulston CPA (Age 47)
    Chief Financial Officer
  • Dr. Glenn Schulman M.P.H.
    Pharm. D., Pharm.D., Senior Vice President of Investor Relations
  • Ms. Mary Weger (Age 65)
    Chief People Officer
  • Dr. Joseph M. Stavas M.D.
    M.P.H., Senior VP of Interventional Procedures & Patient Safety
  • Dr. Darin J. Weber Ph.D. (Age 56)
    Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access
  • Mr. Nikhil L. Pereira-Kamath
    Chief Business Officer
  • Mr. Richard Williams
    Senior Vice President of Information Technology

PROK Stock Analysis - Frequently Asked Questions

Should I buy or sell ProKidney stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" PROK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PROK, but not buy additional shares or sell existing shares.
View PROK analyst ratings
or view top-rated stocks.

What is ProKidney's stock price target for 2024?

3 Wall Street analysts have issued 12 month price objectives for ProKidney's shares. Their PROK share price targets range from $3.00 to $16.00. On average, they predict the company's stock price to reach $9.50 in the next year. This suggests a possible upside of 181.9% from the stock's current price.
View analysts price targets for PROK
or view top-rated stocks among Wall Street analysts.

How have PROK shares performed in 2024?

ProKidney's stock was trading at $1.78 at the beginning of 2024. Since then, PROK stock has increased by 89.3% and is now trading at $3.37.
View the best growth stocks for 2024 here

When is ProKidney's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our PROK earnings forecast

How were ProKidney's earnings last quarter?

ProKidney Corp. (NASDAQ:PROK) posted its earnings results on Thursday, March, 21st. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.10.

Who are ProKidney's major shareholders?

ProKidney's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.79%) and Zullo Investment Group Inc. (0.01%). Insiders that own company stock include Chamath Palihapitiya, Control Empresarial De Capital and Darin J Weber.
View institutional ownership trends

How do I buy shares of ProKidney?

Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PROK) was last updated on 5/25/2024 by Staff

From Our Partners